159 related articles for article (PubMed ID: 30928630)
41. Embelin sensitizes acute myeloid leukemia cells to TRAIL through XIAP inhibition and NF-κB inactivation.
Yang T; Lan J; Huang Q; Chen X; Sun X; Liu X; Yang P; Jin T; Wang S; Mou X
Cell Biochem Biophys; 2015 Jan; 71(1):291-7. PubMed ID: 25358405
[TBL] [Abstract][Full Text] [Related]
42. OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis.
Bai LY; Weng JR; Chiu CF; Wu CY; Yeh SP; Sargeant AM; Lin PH; Liao YM
Biochem Pharmacol; 2013 Nov; 86(10):1430-40. PubMed ID: 24041743
[TBL] [Abstract][Full Text] [Related]
43. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
[TBL] [Abstract][Full Text] [Related]
44. The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.
Zhang W; Borthakur G; Gao C; Chen Y; Mu H; Ruvolo VR; Nomoto K; Zhao N; Konopleva M; Andreeff M
Cancer Res; 2016 Mar; 76(6):1528-37. PubMed ID: 26822154
[TBL] [Abstract][Full Text] [Related]
45. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells.
Long B; Wang LX; Zheng FM; Lai SP; Xu DR; Hu Y; Lin DJ; Zhang XZ; Dong L; Long ZJ; Tong XZ; Liu Q
Cell Physiol Biochem; 2016; 38(4):1288-302. PubMed ID: 27008269
[TBL] [Abstract][Full Text] [Related]
46. Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
Fouladi F; Jehn LB; Metzelder SK; Hub F; Henkenius K; Burchert A; Brendel C; Stiewe T; Neubauer A
Leuk Lymphoma; 2015; 56(9):2690-8. PubMed ID: 25665465
[TBL] [Abstract][Full Text] [Related]
47. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
48. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
49. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
[TBL] [Abstract][Full Text] [Related]
50. Targeting of mTORC1/2 by dihydroevocarpine induces cytotoxicity in acute myeloid leukemia.
Zhang S; Xiong Y; Zhang Y; Zhao H
J Cell Physiol; 2019 Aug; 234(8):13032-13041. PubMed ID: 30548613
[TBL] [Abstract][Full Text] [Related]
51. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
Han L; Qiu P; Zeng Z; Jorgensen JL; Mak DH; Burks JK; Schober W; McQueen TJ; Cortes J; Tanner SD; Roboz GJ; Kantarjian HM; Kornblau SM; Guzman ML; Andreeff M; Konopleva M
Cytometry A; 2015 Apr; 87(4):346-56. PubMed ID: 25598437
[TBL] [Abstract][Full Text] [Related]
52. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells.
Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
Autophagy; 2017 Apr; 13(4):761-762. PubMed ID: 28118076
[TBL] [Abstract][Full Text] [Related]
53. l-Asparaginase-mediated downregulation of c-Myc promotes 1,25(OH)
Song JH; Park E; Kim MS; Cho KM; Park SH; Lee A; Song J; Kim HJ; Koh JT; Kim TS
Int J Cancer; 2017 May; 140(10):2364-2374. PubMed ID: 28224619
[TBL] [Abstract][Full Text] [Related]
54. Overexpression of miRNA-497 inhibits tumor angiogenesis by targeting VEGFR2.
Tu Y; Liu L; Zhao D; Liu Y; Ma X; Fan Y; Wan L; Huang T; Cheng Z; Shen B
Sci Rep; 2015 Sep; 5():13827. PubMed ID: 26345385
[TBL] [Abstract][Full Text] [Related]
55. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
56. Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases.
Liu W; Lu Y; Chai X; Liu X; Zhu T; Wu X; Fang Y; Liu X; Zhang X
J Exp Clin Cancer Res; 2016 Nov; 35(1):183. PubMed ID: 27887633
[TBL] [Abstract][Full Text] [Related]
57. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
[TBL] [Abstract][Full Text] [Related]
58. Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.
Yuan T; Qi B; Jiang Z; Dong W; Zhong L; Bai L; Tong R; Yu J; Shi J
Eur J Med Chem; 2019 Sep; 178():468-483. PubMed ID: 31207462
[TBL] [Abstract][Full Text] [Related]
59. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
[No Abstract] [Full Text] [Related]
60. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
